Skip to content

Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)

Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)

Status
Suspended
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02313116
Enrollment
50
Registered
2014-12-09
Start date
2014-04-30
Completion date
2020-03-18
Last updated
2019-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Lumpectomy, Breast cancer, Optical coherence tomography, Tumor margin, Imaging

Brief summary

This intraoperative study is a prospective study analyzing specimens from fifty subjects. Patients scheduled to undergo breast-conserving surgery will be recruited in accordance with the inclusion and exclusion criteria. The study period per subject is the time it takes to assess the ex vivo breast tissue sample using the study device. Image review will be conducted during surgery and compared to the margin status findings in the post-operative pathology report.

Interventions

DEVICEInterferometric Synthetic Aperture Microscopy

Optical coherence tomography with interferometric synthetic aperture microscopy will be used to image ex vivo breast tissue specimens.

Sponsors

Diagnostic Photonics, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Women 18 years of age or older 2. Signed informed consent form 3. Women who have been histologically diagnosed with carcinoma of the breast prior to surgery 4. Patients planning breast preservation and undergoing lumpectomy (partial mastectomy) procedure

Exclusion criteria

1. Multicentric disease (histologically diagnosed cancer in two different quadrants of the breast) 2. Neoadjuvant systemic therapy 3. All T4 tumors 4. Previous radiation in the operated breast 5. Prior surgical procedure in the same quadrant 6. Implants in the operated breast 7. Pregnancy 8. Lactation 9. Participating in any other investigational study for either drug or device which can influence collection of valid data under this study

Design outcomes

Primary

MeasureTime frame
Patients With All Positive/Close Margins Correctly Identified With the Device1 week after surgery
Number of Margins With False Positive Device Readings1 week after surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026